GLPwatch
Papers (10404)
Page 85 of 174, ranked by citation count.
- Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
- GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024.
- Individualised incretin-based treatment for type 2 diabetes.
- A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.
- Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.
- Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells.
- Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.
- Data mining study on adverse events of tirzepatide based on FAERS database.
- Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
- The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
- Wegovy: FDA approves weight loss drug to cut cardiovascular risk.
- Exendin-4 attenuates ischemia-induced ventricular arrhythmias in rats.
- Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.
- Noninvasive longitudinal quantification of β-cell mass with [<sup>111</sup>In]-labeled exendin-4.
- Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.
- Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes.
- Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy.
- The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.
- Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
- Exendin-4 promotes proliferation of adipose-derived stem cells through ERK and JNK signaling pathways.
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
- The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.
- Effect of Liraglutide in Different Abdominal Fat Layers Measured by Ultrasound: The Importance of Perirenal Fat Reduction.
- Semaglutide: A Novel Oral Glucagon-Like Peptide Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
- Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner.
- A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
- Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.
- Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.
- Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
- A new approach to disease-modifying drug trials in Parkinson's disease.
- An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.
- A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
- An accidental liraglutide overdose: case report.
- The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea.
- iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
- Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.
- SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease.
- Obesity and diabetes: the final frontier.
- Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.
- GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.
- Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
- Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.
- Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.
- Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.
- Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4.
- Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release.
- Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy.
- A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers.
- Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.
- Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
- Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
- Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis.
- Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.
- Alternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model.
- Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.
- Antidiabetic effects of quercetin and liraglutide combination through modulation of TXNIP/IRS-1/PI3K pathway.